Lucentis Approved in Europe to Treat Patients With Macular Edema Secondary to Retinal Vein Occlusion
March 21, 2011
Novartis announced Friday that it had received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Lucentis® (ranibizumab) to treat patients in the European Union with visual impairment due to macular edema secondary to retinal vein occlusion (RVO).
Lucentis was shown to improve vision and vision related quality of life for patients with visual impairment due to macular edema secondary to both branch-RVO (BRVO) and central-RVO (CRVO) in two Phase III studies in patients with BRVO (BRAVO) and CRVO (CRUISE). These studies showed that approximately 60% of BRVO and 48% of CRVO patients treated with monthly Lucentis gained at least 15 letters of visual acuity at six months, compared with 29% and 17% of those treated according to current standard practice, respectively. Patients maintained their visual acuity gains through to 12 months with as-needed dosing of Lucentis.
Read the full press release.
Comments
Jump down to form below to submit your own comments
